Definition and validation of "favorable high-risk prostate cancer": Implications for personalizing treatment of radiation-managed patients

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 4, 2015, Pages 828-835

  Muralidhar, Vinayak ^a   Chen, Ming Hui ^b   Reznor, Gally ^c   Moran, Brian J ^d   Braccioforte, Michelle H ^d   Beard, Clair J ^c   Feng, Felix Y ^e   Hoffman, Karen E ^f   Choueiri, Toni K ^c   Martin, Neil E ^c   Sweeney, Christopher J ^c   Trinh, Quoc Dien ^c   Nguyen, Paul L ^c  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Prostate Cancer Foundation of Chicago   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASE CONTROL; HEALTH INSURANCE; PATIENT TREATMENT; RADIOTHERAPY; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; CLASSIFICATION SYSTEM; CONFIDENCE INTERVAL; HIGH-RISK PROSTATE CANCERS; INTERMEDIATE RISKS; METHODS AND MATERIALS; PROSTATE ADENOCARCINOMAS; PROSTATE SPECIFIC ANTIGEN;

DISEASES;

GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER REGISTRY; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TREATMENT DURATION; BLOOD; CANCER GRADING; CLASSIFICATION; CONFIDENCE INTERVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; VALIDATION STUDY;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CONFIDENCE INTERVALS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PRECISION MEDICINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEER PROGRAM;

EID: 84948425538     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.07.2281     Document Type: Article

References (30)

1. . National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Prostate Cancer. Fort Washington, PA: NCCN; 2015.
2. . Heidenreich A, Bellmunt J , Bolla M, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
3. . Joniau S, Briganti A, Gontero P, et al. Stratification of high-risk prostate cancer into prognostic categories: A European multiinstitutional study. Eur Urol 2015;67:157-164.
4. . Bolla M, De Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516-2527.
5. . Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-3978.
6. . Zapate ro A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:320-327.
7. . Greene DE, Mayadev JS, Valicenti RK. Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol 2012;4: 113-124.
8. . Nguyen PL, Al ibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67: 825-836.
9. . Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013;310:289-296.
10. . Lee M, Jim HS, Fishman M, et al. Depressive symptomatology in men receiving andr ogen deprivation therapy for prostate cancer: A controlled comparison. Psychooncology 2015;24:472-477.
11. . Zhang J, Hricak H, Shukla-Dave A, et al. Clinical stage T1c prostate cancer: Evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009;253:425-434.
12. . Pierorazio PM, Ross AE, Han M, et al. Evolution of the clinical presentation of men undergoing radical pro statectomy for high-risk prostate cancer. BJU Int 2012;109:988-993.
13. Nanda A,Chen MH,Renshaw AA,et al. Gleason Pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials Int J Radiat Oncol Biol Phys 2009; 74 1419-1423.
14. . Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 2013;64:895-902.
15. . Surveillance, Epidemiology, and End Results (SEER). Overview of the SEER Program. Available at: http://seer.cancer.gov/about/overview.html. Accessed August 19, 2015.
16. . Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEERMedicare data: Content, research applications, and generalizability to the United States elderly population. Med Ca re 2002;40(8 Suppl). IV-3-18.
17. . National Cancer Institute. PSA values and SEER data. Surveillance, Epidemiology, and End Results Program. Updated April 29th, 2015. Available at: http://seer.cancer.gov/data/psa-values.html. Accessed May 12, 2015.
18. . Furlow B. US National Cancer Institute investigates PSA coding errors. Lancet Oncol 2015;16:614.
19. . Schymura MJ, Sun L, Percy-Laurry A. Prostate cancer collaborative stage data itemsetheir definitions, quality, usage, and clinical implications: A review of SEER data for 2004-2010. Cancer 2014; 120(Suppl 23):3758-3770.
20. . Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
21. . D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppressio n plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292:821-827.
22. . Jones CU, Hunt D, Mcgowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-118.
23. . Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910. J Clin Oncol 2015;33:332-339.
24. . D'Amico AV. Personalizing the duration of androgen-deprivation therapy use in the management of intermediate-risk prostate cancer. J Clin Oncol 2015;33:301-303.
25. . Raldow AC, Zhang D, Chen M, et al. Risk group and death from prostate cancer: Implicat ions for active surveillance in men with favorable intermediate-risk prostate cancer. JAMA Oncol 2015;1: 334-340.
26. . Keane FK, Chen MH, Zhang D, et al. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer 2014;120:1787-1793.
27. . Nabid A, Carrier N, Martin AG, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial. J Clin Oncol 2013;31(Suppl):LBA4510.
28. Muralidhar V, Dinh KT, Mahal BA, et al. Differential postprostatectomy cancer-specific survival of occult T3 versus clinical T3 prostate cancer: Implications for managing patients upstaged on prostate MRI. Urol Oncol 2015; 33:330.-19-330.-25.
29. . Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: A European multi-institutional study of 7 12 patients. Eur Urol 2010;58:1-7.
30. . Walz J, Joniau S, Chun FK, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011;107:765-770.